cerrar
Tagged with IMI

The Rise of Chinese Biosimilars
The Chinese healthcare market has transformed dramatically in the past few years. There have been many reforms centred around the country’s vision…

Biosimilar Uptake in Europe: Big Challenges; Bigger Rewards
Isabell Remus, chair of the Biosimilar Medicines Group at Medicines for Europe outlines the issues that need to be addressed to keep driving…

Chip Davis – President & CEO, Association for…
The AAM's Chip Davis gives an account of his agenda for 2020, how the association is driving policy in a complex healthcare environment of multiple…

Biocon’s New Facility & Expansion in APAC
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an…

Gábor Orbán – CEO, Gedeon Richter
Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company's performance, its exciting new collaboration with Allergan in…

István Hodász – CEO, Egis
István Hodász, CEO of Egis Pharmaceuticals PLC, introduces the longstanding history of the company and its positioning as a leading manufacturer of…

Jiří Hanzlík – Country Head, Sandoz Czech Republic
Sandoz’s Jiří Hanzlík, country head for the Czech Republic, evaluates the Czech affiliate’s role in contributing to the success of Sandoz…

Jānis Meikšāns – General Manager, Teva Hungary
Jānis Meikšāns, newly appointed general manager of Teva Hungary, speaks about his first few months in the country. Meikšāns goes on to elaborate…

Hungary’s National Champions Betting on Biosimilars
Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European…

Biosimilars Work. Why Aren’t They Taking Off in the US?
The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save…

Beyond Generics: Dr Reddy’s Going Global
Indian generics powerhouse Dr. Reddy’s has prioritized biosimilars as a key component of the global organization’s ongoing transition into a…

Christoph Stoller of Medicines for Europe on Tackling Drug…
Christoph Stoller, general manager for Austria and Germany at Teva was recently elected president of Medicines for Europe, the continent-wide…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here